Document text
Principal Investigator: Emmie De Wit
Organization: NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
Fiscal Year: 2022
Award: $56,623
Funding agency: National Institute of Allergy and Infectious Diseases
In any given year, lower respiratory tract infections are the leading cause of infectious disease deaths worldwide, and the fifth most important cause of death overall. Respiratory viruses keep emerging at a steady pace (e.g. MERS-CoV, enterovirus D68, avian influenza viruses), adding to the burden of respiratory tract infections on global health. In 2019-2020, the emergence of SARS-CoV-2 and the resulting COVID-19 pandemic highlighted how devastating the effect of emerging respiratory viruses on global public health and economies can be. The COVID-19 pandemic also highlighted the difficulty of effectively treating severe viral lower respiratory tract infections. Major advances have been made in our knowledge of the pathogenic processes involved in severe respiratory disease over the past decade; however, few successful treatments have made their way into the clinic. Although many clinical trials have been performed and are ongoing in COVID-19 patients, very few of those have generated promising results. Even those therapeutics tested with positive outcomes, showed benefits only in a fraction of patients. Thus, it is clear that our current understanding of the pathogenesis of viral lower respiratory tract infections is insufficient to drive the development of effective treatments.
In the past year, our research has mainly focused on four aspects of COVID-19: model development, pathogenesis, support of NIH clinical work, and efficacy of potential antiviral treatments.
In terms of model development, we have successfully established 3D small airway and alveolar organoids from 4 human donors. We have characterized the cellular make-up of these organoids and shown that they express markers typical of type II pneumocytes, and the receptor for SARS-CoV-2, ACE2. We have tested and optimized procedures for infection of the 3D organoids with SARS-CoV-2 and testing their viability during virus infection. We compared the ability of B.1.1.529 (Omicron) to replicate in human lung epithelium, cause cell death and induce pro-inflammatory cytokines to that of B.1.629 (Delta) and D614G (ancestral clade B.1 virus). B.1.1.529 was severely attenuated in the alveolar organoids compared to B.1.629 and D614G, and was only able to replicate to low titers in one of four donors. This is consistent with early reports of reduced B.1.1.529 replication in the lower respiratory tract of rodents, and a milder clinical course of disease in humans. In contrast, B.1.629 consistently replicated faster and to higher titers compared to B.1.1.529 and D614G in all donors tested. Despite high levels of virus replication, we did not observe significant host cell death in organoids infected with any variant. We are currently comparing the production of cytokines in the organoids infected with the different isolates and analyzing the host response to infection using transcriptomics, hoping to identify pathways underlying the differences in replicative ability between variants and hosts.
Our pathogenesis studies focused on the pathogenicity of Variants of Concern and why increased age is a major risk factor for developing severe COVID-19. SARS-CoV-2 variants B.1.1.7 (Alpha) and B.1.351 (Beta) were both classified as Variant of Concern (VOC), based on their rapid spread in the population and reports on increased hospitalization rates. To compare the pathogenicity and virus shedding of VOC B.1.1.7 and B.1.351, we inoculated three groups of six rhesus macaques intranasally and intratracheally with three different SARS-CoV-2 isolates: D614G, a B.1.1.7 isolate, and a B.1.351 isolate. The B.1.1.7 VOC behaved similarly to the D614G with respect to clinical disease, virus shedding and virus replication in the respiratory tract. Inoculation with the B.1.351 isolate resulted in lower clinical scores in rhesus macaques that correlated with lower virus titers in the lungs, less severe histologic lung lesions and less viral antigen detected in the lungs. In bronchoalveolar lavages, cytokines and chemokines were upregulated on day 4 in animals inoculated with D614G and B.1.1.7 but not in those inoculated with B.1.351. In nasal samples, we did not detect upregulation of cytokines and chemokines in D614G or B.1.351-inoculated animals. However, cytokines and chemokines were upregulated in the noses of B.1.1.7-inoculated animals.
To investigate the effect of age on the pathogenesis of SARS-CoV-2 infection, we inoculated eight aged (16-23 years) and eight subadult (3-5 years) rhesus macaques with SARS-CoV-2. We then used a multi-omics approach to gain a complete picture of the host response to SARS-CoV-2 in the lungs and systemically. Although older animals displayed slightly elevated clinical scores over the course of infection and recovery was somewhat slower, differences in clinical signs, pulmonary infiltrates, and virus replication dynamics were limited between the two age groups. Despite this limited effect of age on disease outcome, we found several striking differences in the response to SARS-CoV-2 infection through immunological and transcriptional profiling. During the acute phase of SARS-CoV-2 infection in the older animals, the local innate immune response was upregulated in both immune and non-immune cell populations through 7 dpi. In contrast, the younger animals appeared to better control the innate inflammatory response in the lungs, as evidenced by the more attenuated induction of innate pathways that occurred only in immune cells, and resolving it by 7 dpi. During the post-acute phase of the disease, the two groups diverged further, with older animals exhibiting a prolonged pro-inflammatory circulating response, as well as a delay in the activation and/or differentiation of T-cells isolated from the lungs. Concomitant with these changes within the T-cell compartment, the younger animals displayed a pro-resolving circulating milieu of lipid mediators and cytokines at later timepoints, while the older animals did not.
We supported several clinical studies with our standardized SARS-CoV-2 assays. We helped the NIH Clinical Center to answer questions about the use of SARS-CoV-2 diagnostics for return-to-work testing early in the pandemic, as well as helping to compare the reliability of saliva swabs versus nasopharyngeal swabs for diagnostic purposes. We also supported studies showing long-term shedding of infectious SARS-CoV-2 virus in immunocompromised patients.
Finally, we completed a study assessing the efficacy of subcutaneous remdesivir treatment, as a potential replacement for intravenous administration. Two groups of six rhesus macaques were inoculated with SARS-CoV-2 and treated according to the same dosing schedule as used for intravenous remdesivir. Pharmacokinetic analyses of remdesivir and its main metabolites in the rhesus macaques indicated that the release of remdesivir is somewhat slower with subcutaneous administration, but that plasma levels persist longer. Additionally, the active triphosphate metabolite concentration in the lungs was similar with subcutaneous and intravenous administration. Compared to vehicle-treated animals, macaques treated with subcutaneous remdesivir from 12 hours through 6 days post inoculation showed reduced signs of respiratory disease, a reduction of virus replication in the lower respiratory tract, and an absence of interstitial pneumonia.
Terms: <2019 novel corona virus><2019 novel coronavirus><2019-nCoV><2019-nCoV variant><2019-nCoV variant forms><2019-nCoV variant strains><3-D><3-Dimensional><3D><ACE2><Acute><Address><Age><Airway infections><Alveolar><Animal Model><Animal Models and Related Studies><Animals><Attenuated><Avian Influenza A Virus><Avian Influenza Virus><Avian Orthomyxovirus Type A><B.1.1.7><B.1.351><Biologic Models><Biological Models><Blood Plasma><Bronchioalveolar Lavage><Bronchoalveolar Lavage><Bronchopulmonary Lavage><COVID crisis><COVID epidemic><COVID infected patient><COVID pandemic><COVID patient><COVID positive patient><COVID-19><COVID-19 assay><COVID-19 crisis><COVID-19 diagnostic><COVID-19 epidemic><COVID-19 global health crisis><COVID-19 global pandemic><COVID-19 health crisis><COVID-19 infected patient><COVID-19 infection><COVID-19 pandemic><COVID-19 patient><COVID-19 positive patient><COVID-19 public health crisis><COVID-19 testing><COVID-19 variant><COVID-19 variant forms><COVID-19 variant strains><COVID-19 virus><COVID19><COVID19 assay><COVID19 crisis><COVID19 diagnostic><COVID19 epidemic><COVID19 global health crisis><COVID19 global pandemic><COVID19 health crisis><COVID19 infection><COVID19 pandemic><COVID19 patient><COVID19 positive patient><COVID19 public health crisis><COVID19 testing><COVID19 virus><CV-19><CV19><Cause of Death><Cell Body><Cell Compartmentation><Cell Compartmentations><Cell Death><Cells><Cessation of life><Chemotactic Cytokines><Clinic><Clinical><Clinical Course of Disease><Clinical Research><Clinical Study><Clinical Trials><CoV-2><CoV2><Communicable Diseases><Coronaviridae><Coronavirus><Data><Death><Development><Diagnostic><Disease><Disease Outcome><Disease Progression><Disorder><Dose><Drug Kinetics><Enterovirus 68><Enterovirus D68><Epithelial><Exhibits><Fowl Plague Virus><GS-5734><Gene Expression Monitoring><Gene Expression Pattern Analysis><Gene Expression Profiling><Goals><Histologic><Histologically><Homologous Chemotactic Cytokines><Hour><Human><Immune><Immune response><Immunes><Immunochemical Immunologic><Immunocompromised><Immunocompromised Host><Immunocompromised Patient><Immunologic><Immunological><Immunological response><Immunologically><Immunologics><Immunosuppressed Host><Individual><Infection><Infectious Disease Pathway><Infectious Diseases><Infectious Disorder><Inflammatory><Inflammatory Response><Influenza A><Influenza A virus><Influenza Viruses Type A><Influenzavirus A><Innate Immune Response><Intercrines><Interstitial Lung Inflammation><Interstitial Pneumonia><Interstitial Pneumonitis><Interstitial Pulmonary Inflammation><Intravenous><Knowledge><Lower Respiratory Tract Infection><Lower respiratory infection><Lower respiratory tract structure><Lung><Lung Lavage><Lung Respiratory System><M mulatta><M. mulatta><MERS corona virus><MERS coronavirus><MERS virus><MERS-CoV><Macaca><Macaca mulatta><Macaque><Middle East Respiratory Syndrome Corona Virus><Middle East Respiratory Syndrome Coronavirus><Middle East Respiratory Syndrome Virus><Middle East Respiratory Syndrome-CoV><Middle Eastern Respiratory Syndrome Corona virus><Middle Eastern Respiratory Syndrome Coronavirus><Middle Eastern Respiratory Syndrome Virus><Middle Eastern Respiratory Syndrome-CoV><Model System><Modern Man><Molecular><Myxovirus pestis galli><NIH><Nasal><Nasal Passages Nose><National Institutes of Health><Nipah Virus><Nose><Organ><Organoids><Orthomyxovirus Type A><Outcome><Pathogenesis><Pathogenicity><Pathway interactions><Patients><Pharmacokinetics><Phase><Plasma><Plasma Serum><Population><Procedures><Process><Production><Public Health><Pulmonary Body System><Pulmonary Organ System><Receptor Protein><Recovery><Reporting><Research><Respiratory Disease><Respiratory Infections><Respiratory System><Respiratory System Disease><Respiratory System Disorder><Respiratory System, Nose, Nasal Passages><Respiratory Tract Diseases><Respiratory Tract Infections><Respiratory Tracts><Respiratory tract structure><Reticuloendothelial System, Serum, Plasma><Rhesus Macaque><Rhesus Monkey><Risk Factors><Rodent><Rodentia><Rodents Mammals><SARS corona virus 2><SARS-CO-V2><SARS-COVID-2><SARS-CoV-2><SARS-CoV-2 B.1.1.7><SARS-CoV-2 B.1.351><SARS-CoV-2 alpha><SARS-CoV-2 assay><SARS-CoV-2 beta><SARS-CoV-2 diagnostic><SARS-CoV-2 epidemic><SARS-CoV-2 global health crisis><SARS-CoV-2 global pandemic><SARS-CoV-2 infected patient><SARS-CoV-2 infection><SARS-CoV-2 pandemic><SARS-CoV-2 pathogenesis><SARS-CoV-2 patient><SARS-CoV-2 positive patient><SARS-CoV-2 testing><SARS-CoV-2 variant><SARS-CoV-2 variant forms><SARS-CoV-2 variant strains><SARS-CoV2><SARS-CoV2 epidemic><SARS-CoV2 infection><SARS-CoV2 pandemic><SARS-associated corona virus 2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-coronavirus-2 epidemic><SARS-coronavirus-2 pandemic><SARS-related corona virus 2><SARS-related coronavirus 2><SARSCoV2><SIS cytokines><Saliva><Sampling><Schedule><Severe Acute Respiratory Coronavirus 2><Severe Acute Respiratory Distress Syndrome CoV 2><Severe Acute Respiratory Distress Syndrome Corona Virus 2><Severe Acute Respiratory Distress Syndrome Coronavirus 2><Severe Acute Respiratory Syndrome CoV 2><Severe Acute Respiratory Syndrome CoV 2 epidemic><Severe Acute Respiratory Syndrome CoV 2 pandemic><Severe Acute Respiratory Syndrome-associated coronavirus 2><Severe Acute Respiratory Syndrome-related coronavirus 2><Severe acute respiratory syndrome associated corona virus 2><Severe acute respiratory syndrome corona virus 2><Severe acute respiratory syndrome coronavirus 2><Severe acute respiratory syndrome coronavirus 2 epidemic><Severe acute respiratory syndrome coronavirus 2 infection><Severe acute respiratory syndrome coronavirus 2 pandemic><Severe acute respiratory syndrome related corona virus 2><South Africa strain><South Africa variant><South African strain><South African variant><Standardization><Swab><Syndrome><T cell differentiation><T-Cells><T-Lymphocyte><Testing><Therapeutic><Transcript Expression Analyses><Transcript Expression Analysis><Type A Influenza><Type II Pneumocyte><U.K. variant><UK strain><UK variant><United Kingdom variant><United States National Institutes of Health><Up-Regulation><Upregulation><Variant><Variation><Veklury><Viral><Viral Antigens><Viral Diseases><Viral Pathogenesis><Viral Shedding><Virus><Virus Diseases><Virus Replication><Virus Shedding><Work><Wuhan coronavirus><age effect><age group><aged><ages><aging effect><alveolar type II cell><angiotensin converting enzyme 2><angiotensin converting enzyme II><animal data><antigen based detection><antigen detection><avian flu virus><base><bird flu virus><bronchopulmonary lavage therapy><chemoattractant cytokine><chemokine><clinical center><corona virus><corona virus disease 2019><corona virus disease 2019 epidemic><corona virus disease 2019 pandemic><coronavirus disease 2019><coronavirus disease 2019 assay><coronavirus disease 2019 crisis><coronavirus disease 2019 diagnostic><coronavirus disease 2019 epidemic><coronavirus disease 2019 global health crisis><coronavirus disease 2019 global pandemic><coronavirus disease 2019 health crisis><coronavirus disease 2019 infected patient><coronavirus disease 2019 infection><coronavirus disease 2019 pandemic><coronavirus disease 2019 patient><coronavirus disease 2019 positive patient><coronavirus disease 2019 public health crisis><coronavirus disease 2019 testing><coronavirus disease 2019 variant><coronavirus disease 2019 variant forms><coronavirus disease 2019 variant strains><coronavirus disease 2019 virus><coronavirus disease crisis><coronavirus disease epidemic><coronavirus disease infected patient><coronavirus disease pandemic><coronavirus disease patient><coronavirus disease positive patient><coronavirus disease-19><coronavirus disease-19 global pandemic><coronavirus disease-19 pandemic><coronavirus disease-19 patient><coronavirus disease-19 virus><coronavirus infectious disease-19><coronavirus patient><cytokine><detect antigen><developmental><druggable target><effective therapy><effective treatment><gene expression analysis><gene expression assay><global health><hCoV19><hospitalization rates><host response><immune system response><immunoresponse><immunosuppressed patient><in vitro Model><infected with COVID-19><infected with COVID19><infected with SARS-CoV-2><infected with SARS-CoV2><infected with coronavirus disease 2019><infected with severe acute respiratory syndrome coronavirus 2><insight><intravenous administration><juvenile animal><life-threatening COVID><life-threatening COVID-19><life-threatening SARS-CoV-2><life-threatening coronavirus disease><life-threatening coronavirus disease 2019><life-threatening severe acute respiratory syndrome coronavirus 2><lipid mediator><lower respiratory tract><lung lesion><model development><model of animal><model organism><multiomics><multiple omics><nCoV2><nasopharyngeal swab><necrocytosis><pandemic><pandemic disease><pathogenic virus><pathway><patient infected with COVID><patient infected with COVID-19><patient infected with SARS-CoV-2><patient infected with coronavirus disease><patient infected with coronavirus disease 2019><patient infected with severe acute respiratory syndrome coronavirus 2><patient with COVID><patient with COVID-19><patient with COVID19><patient with SARS-CoV-2><patient with coronavirus disease><patient with coronavirus disease 2019><patient with severe acute respiratory distress syndrome coronavirus 2><pulmonary><pulmonary lesion><receptor><remdesivir><respiratory virus><response><serious COVID><serious COVID-19><serious SARS-CoV-2><serious coronavirus disease><serious coronavirus disease 2019><serious severe acute respiratory syndrome coronavirus 2><severe COVID><severe COVID-19><severe COVID19><severe SARS-CoV-2><severe acute respiratory syndrome coronavirus 2 B.1.1.7><severe acute respiratory syndrome coronavirus 2 B.1.351><severe acute respiratory syndrome coronavirus 2 assay><severe acute respiratory syndrome coronavirus 2 diagnostic><severe acute respiratory syndrome coronavirus 2 global health crisis><severe acute respiratory syndrome coronavirus 2 global pandemic><severe acute respiratory syndrome coronavirus 2 infected patient><severe acute respiratory syndrome coronavirus 2 pathogenesis><severe acute respiratory syndrome coronavirus 2 patient><severe acute respiratory syndrome coronavirus 2 positive patient><severe acute respiratory syndrome coronavirus 2 testing><severe acute respiratory syndrome coronavirus 2 variant><severe acute respiratory syndrome coronavirus 2 variant forms><severe acute respiratory syndrome coronavirus 2 variant strains><severe coronavirus disease><severe coronavirus disease 19><severe coronavirus disease 2019><severe severe acute respiratory syndrome coronavirus 2><subcutaneous><subdermal><therapeutic evaluation><therapeutic testing><three dimensional><thymus derived lymphocyte><transcriptional profiling><transcriptomics><triphosphate><tripolyphosphate><variants of concern><viral infection><viral multiplication><viral pathogen><viral replication><virus antigen><virus infection><virus multiplication><virus pathogen><virus pathogenesis><virus-induced disease><young animal>